Female Sexual Dysfunction Treatment Market Introduction and Overview
According to SPER Market Research, the Global Female Sexual Dysfunction Treatment Market is estimated to reach USD XX Billion by 2033 with a CAGR of XX%.
The report includes an in-depth analysis of the Global Female Sexual Dysfunction Treatment Market, including market size and trends, product mix, applications, and supplier analysis. Female sexual dysfunction refers to a variety of problems that can significantly affect a woman's quality of life and general well-being. It can cause emotional pain, strained relationships, and low self-esteem. Recognising the significance of tackling this issue, the healthcare industry has seen the development of multiple treatment solutions that address various aspects of female sexual dysfunction.
- January 2023: Mayne Pharma Group Limited has announced the completion of its exclusive product licencing agreement with TherapeuticsMD, Inc. Mayne Pharma Group Limited has acquired a portfolio of three patent-protected new women's health drugs, including IMVEXXY, through the exclusive licence arrangement.
- September 2022: Freya Pharma Solutions obtained early scientific guidance from the European Medicines Agency (EMA) on its forthcoming phase 3 clinical trial to confirm Lybrido's efficacy in women suffering from FSIAD.
Market Opportunities and Challenges
The female sexual dysfunction therapy industry has many opportunities for growth and expansion. Increased investment in R&D activities has the potential to lead to the launch of new treatment modalities and therapeutic approaches. Furthermore, the growing emphasis on personalised medicine and the creation of customised treatment solutions adapted to individual needs may open up new opportunities for market participants. Collaborations between pharmaceutical corporations and healthcare professionals can also aid in the development of novel and complete treatment solutions.
Increased awareness of female sexual dysfunctions among women is likely to drive market growth over the forecast period. The International Society for Sexual Medicine is a key player in promoting evidence-based scientific advances in sexual medicine around the world, addressing both male and female practitioners and patients. The organization's goal is to increase sexual health awareness, understanding, and support through improved communication and marketing. The "Right to Desire" campaign, funded by Sprout Pharmaceuticals, teaches women about sexual dysfunction. Similarly, the Find My Spark programme, developed by W2O Group and the American Sexual Health Association, promotes frank discussions about sexual issues, which aids market growth.
Despite the good market forecast, certain obstacles limit the growth of the female sexual dysfunction therapy industry. One of the most significant obstacles is the stigma associated with addressing sexual health issues, which frequently inhibits women from getting necessary care. Limited access to healthcare services and high treatment costs are further impediments to market expansion, especially in underdeveloped countries. Furthermore, the lack of globally accepted diagnostic criteria and treatment protocols hinders consistent and standardised treatment techniques.
Market Competitive Landscape
The female sexual dysfunction therapy market has a competitive landscape that includes both established pharmaceutical corporations and developing players. Key market participants are focusing on product innovation, strategic alliances, and mergers and acquisitions to obtain a competitive advantage. Furthermore, the release of generic copies of existing pharmaceuticals, as well as the development of cost-effective treatment choices, is driving up market competitiveness. The major key players in the Global Female Sexual Dysfunction Treatment Market are: AMAG Pharmaceuticals Inc., Apricus Biosciences, Inc., Cipla Inc., Duchesnay Inc., Emotional Brain BV, GlaxoSmithKline, Plc, Merck & Co., Inc., Novo Nordisk AS, Pfizer, Inc., Pivot Pharmaceuticals Inc., Sprout Pharmaceuticals, Inc, Others.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2020-2033 |
| Base year considered | 2023 |
| Forecast period | 2024-2033 |
| Segments covered | By Type, By Indication, By Age
|
| Regions covered | Asia-Pacific, Europe, Middle East and Africa, North America, Latin America
|
| Companies Covered | AMAG Pharmaceuticals Inc., Apricus Biosciences, Inc., Cipla Inc., Duchesnay Inc., Emotional Brain BV, GlaxoSmithKline, Plc, Merck & Co., Inc., Novo Nordisk AS, Pfizer, Inc., Pivot Pharmaceuticals Inc., Sprout Pharmaceuticals, Inc, Others.
|
COVID-19 Impact on Global Female Sexual Dysfunction Treatment Market
The COVID-19 pandemic has had varying effects on the female sexual dysfunction treatment market. While the initial part of the pandemic disrupted healthcare services and reduced patient visits, there has been a greater emphasis on telehealth and virtual consultations. The epidemic has highlighted the need of addressing sexual health concerns and prompted the creation of remote treatment options. Economic uncertainty and difficulty in allocating healthcare resources have had an impact on market growth.
Key Target Audience:
- Healthcare Providers (Gynecologists, Urologists, Endocrinologists, Psychiatrists, etc.)
- Pharmaceutical Companies and Drug Manufacturers
- Women's Health Organizations and Advocacy Groups
- Sexual Health Clinics and Centers
- Mental Health Professionals (Psychologists, Counselors, Therapists, etc.)
- Patients and Consumers
- Others
Our in-depth analysis of the Female Sexual Dysfunction Treatment Market includes the following segments:
|
By Type: |
Counselling and Behavioral Therapy
Medication
Others
|
|
By Indication: |
Arousal Disorder
Female Orgasmic Disorder
Hypoactive Sexual Desire Disorder (HSDD)
Penetration (Sexual Pain) Disorder
Others
|
|
By Age: |
18-30 Years
30-45 Years
Above 45 Years
|
Key Topics Covered in the Report:
- Global Female Sexual Dysfunction Treatment Market Size (FY’2024-FY’2033)
- Overview of Global Female Sexual Dysfunction Treatment Market
- Segmentation of Global Female Sexual Dysfunction Treatment Market By Type (Counselling and Behavioral Therapy, Medication, Others)
- Segmentation of Global Female Sexual Dysfunction Treatment Market By Indication (Arousal Disorder, Female Orgasmic Disorder, Hypoactive Sexual Desire Disorder (HSDD), Penetration (Sexual Pain) Disorder, Others)
- Segmentation of Global Female Sexual Dysfunction Treatment Market By Age (18-30 Years, 30-45 Years, Above 45 Years)
- Statistical Snap of Global Female Sexual Dysfunction Treatment Market
- Expansion Analysis of Global Female Sexual Dysfunction Treatment Market
- Problems and Obstacles in Global Female Sexual Dysfunction Treatment Market
- Competitive Landscape in the Global Female Sexual Dysfunction Treatment Market
- Impact of COVID-19 and Demonetization on Global Female Sexual Dysfunction Treatment Market
- Details on Current Investment in Global Female Sexual Dysfunction Treatment Market
- Competitive Analysis of Global Female Sexual Dysfunction Treatment Market
- Prominent Players in the Global Female Sexual Dysfunction Treatment Market
- SWOT Analysis of Global Female Sexual Dysfunction Treatment Market
- Global Female Sexual Dysfunction Treatment Market Future Outlook and Projections (FY’2024-FY’2033)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPER’s internal database
2.1.4. Premium insight from KOL’s
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
4.2. COVID-19 Impacts of the Global Female Sexual Dysfunction Treatment Market
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTER’s Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Female Sexual Dysfunction Treatment Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Female Sexual Dysfunction Treatment Market
7. Global Female Sexual Dysfunction Treatment Market, By Type (USD Million) 2020-2033
7.1. Global Female Sexual Dysfunction Treatment Market Size, Share and Forecast, By Type, 2020-2026
7.2. Global Female Sexual Dysfunction Treatment Market Size, Share and Forecast, By Type, 2027-2033
7.3. Counselling and Behavioral Therapy
7.4. Medication
7.4.1. Hormonal Therapy
7.4.2. Non-Hormonal Therapy
7.5. Others
8. Global Female Sexual Dysfunction Treatment Market, By Indication (USD Million) 2020-2033
8.1. Global Female Sexual Dysfunction Treatment Market Size, Share and Forecast, By Indication, 2020-2026
8.2. Global Female Sexual Dysfunction Treatment Market Size, Share and Forecast, By Indication, 2027-2033
8.3. Arousal Disorder
8.4. Female Orgasmic Disorder
8.5. Hypoactive Sexual Desire Disorder (HSDD)
8.6. Penetration (Sexual Pain) Disorder
8.7. Others
9. Global Female Sexual Dysfunction Treatment Market, By Age (USD Million) 2020-2033
9.1. Global Female Sexual Dysfunction Treatment Market Size, Share and Forecast, By Age, 2020-2026
9.2. Global Female Sexual Dysfunction Treatment Market Size, Share and Forecast, By Age, 2027-2033
9.3. 18-30 Years
9.4. 30-45 Years
9.5. Above 45 Years
10. Global Female Sexual Dysfunction Treatment Market Forecast, 2020-2033 (USD Million)
10.1. Global Female Sexual Dysfunction Treatment Market Size and Market Share
11. Global Female Sexual Dysfunction Treatment Market, By Region, 2020-2033 (USD Million)
11.1. Global Female Sexual Dysfunction Treatment Market Size and Market Share By Region (2020-2026)
11.2. Global Female Sexual Dysfunction Treatment Market Size and Market Share By Region (2027-2033)
11.3. Asia-Pacific
11.3.1. Australia
11.3.2. China
11.3.3. India
11.3.4. Japan
11.3.5. South Korea
11.3.6. Rest of Asia-Pacific
11.4. Europe
11.4.1. France
11.4.2. Germany
11.4.3. Italy
11.4.4. Spain
11.4.5. United Kingdom
11.4.6. Rest of Europe
11.5. Middle East and Africa
11.5.1. Kingdom of Saudi Arabia
11.5.2. United Arab Emirates
11.5.3. Qatar
11.5.4. South Africa
11.5.5. Egypt
11.5.6. Morocco
11.5.7. Nigeria
11.5.8. Rest of Middle East & Africa
11.6. North America
11.6.1. Canada
11.6.2. Mexico
11.6.3. United States
11.7. Latin America
11.7.1. Argentina
11.7.2. Brazil
11.7.3. Rest of Latin America
12. Company Profile
12.1. AMAG Pharmaceuticals Inc
12.1.1. Company details
12.1.2. Financial outlook
12.1.3. Product summary
12.1.4. Recent developments
12.2. Apricus Biosciences, Inc
12.2.1. Company details
12.2.2. Financial outlook
12.2.3. Product summary
12.2.4. Recent developments
12.3. Cipla Inc
12.3.1. Company details
12.3.2. Financial outlook
12.3.3. Product summary
12.3.4. Recent developments
12.4. Duchesnay Inc
12.4.1. Company details
12.4.2. Financial outlook
12.4.3. Product summary
12.4.4. Recent developments
12.5. Emotional Brain BV
12.5.1. Company details
12.5.2. Financial outlook
12.5.3. Product summary
12.5.4. Recent developments
12.6. GlaxoSmithKline, Plc
12.6.1. Company details
12.6.2. Financial outlook
12.6.3. Product summary
12.6.4. Recent developments
12.7. Merck & Co., Inc
12.7.1. Company details
12.7.2. Financial outlook
12.7.3. Product summary
12.7.4. Recent developments
12.8. Novo Nordisk AS
12.8.1. Company details
12.8.2. Financial outlook
12.8.3. Product summary
12.8.4. Recent developments
12.9. Pfizer, Inc
12.9.1. Company details
12.9.2. Financial outlook
12.9.3. Product summary
12.9.4. Recent developments
12.10. Pivot Pharmaceuticals Inc
12.10.1. Company details
12.10.2. Financial outlook
12.10.3. Product summary
12.10.4. Recent developments
12.11. Sprout Pharmaceuticals, Inc.
12.11.1. Company details
12.11.2. Financial outlook
12.11.3. Product summary
12.11.4. Recent developments
12.12. Others
13. List of Abbreviations
14. Reference Links
15. Conclusion
16. Research Scope